Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (Nasdaq:PCRX) announced that, based on preliminary results from its 2026 Annual Meeting of Stockholders, all three company director nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — were elected to the board.
Final results will be certified and filed on Form 8-K with the SEC.
Pacira BioSciences (Nasdaq:PCRX) urges stockholders to vote the BLUE proxy card for its three director nominees ahead of the June 9, 2026 annual meeting. Independent advisors ISS, Glass Lewis and Egan-Jones recommend supporting Pacira’s slate. Pacira highlights record 2025 revenue and margins, Q1 2026 EXPAREL, ZILRETTA and iovera° growth, and upcoming 2026 clinical readouts as reasons to maintain its current board and 5x30 strategy.
Summary not available.
Pacira BioSciences (Nasdaq:PCRX) sent a letter urging stockholders to back its board nominees ahead of the June 9, 2026 annual meeting and support its 5x30 growth strategy.
Pacira highlights 2025 record revenue of $726.4M, GAAP net income of $7.0M, record gross margins, EXPAREL growth, new partnerships, and an EXPAREL patent settlement providing exclusivity into 2030 with a capped transition through 2039.
Pacira BioSciences (NASDAQ:PCRX) reported real-world data on EXPAREL in outpatient total shoulder arthroplasty among more than 6,400 opioid-naïve Medicare Advantage patients. According to Pacira, EXPAREL use was associated with lower opioid consumption, fewer opioid-related adverse events, and reduced 90-day healthcare costs versus standard analgesia.
The retrospective observational study used Optum Clinformatics data from July 2019 to December 2024 and was presented at the ISPOR 2026 Annual Meeting. Pacira notes the analysis identifies associations and may be subject to limitations inherent in claims-based research.
Summary not available.
Summary not available.
DOMA Perpetual Capital Management, which owns about 7.5% of Pacira BioSciences (NASDAQ:PCRX), released a joint letter from independent director nominees Christopher Dennis and Oliver Benton “Ben” Curtis III.
The nominees seek shareholder support via the WHITE proxy card, criticize Pacira’s long-term performance, and highlight Q1 2026 revenue growth of 5%, GAAP net income of $2.9 million, and Adjusted EBITDA of $40.2 million.
Pacira BioSciences (Nasdaq:PCRX) filed an investor presentation ahead of its June 9, 2026 annual meeting, urging stockholders to vote FOR its nominees on the BLUE proxy card.
Key points include 2025 revenue of $726.4M, record GAAP gross margin of 79.4%, 22% total stockholder return since launching the 5x30 plan, Q1 2026 product revenue growth, $200M of share repurchases under a $300M program, an EXPAREL patent settlement securing exclusivity through 2030, advancement of PCRX-201 and PCRX-2002, and a largely independent, recently refreshed board.
Summary not available.